Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 36164

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Original article / research
Year : 2023 | Month : January | Volume : 17 | Issue : 1 | Page : OC36 - OC38 Full Version

Clinical Outcomes of Remdesivir in Moderate and Severe Cases of COVID-19: A Retrospective Cohort Study

Published: January 1, 2023 | DOI:
Ruth Priya Senthiappan, Archana A Dambal, K Mohan, Kiran R Aithal, Rajendra Kumar Parakh, Bhargav Vuppumalla

1. Assistant Professor, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India. 2. Professor, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India. 3. Professor, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India. 4. Professor and Head, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India. 5. Professor, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India. 6. Postgraduate Resident, Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India.

Correspondence Address :
Dr. Ruth Priya Senthiappan,
17 B, Vijay Nagar Vishweshwar Nagar, Dharwad, Karnataka, India.


Introduction: Remdesivir is a nucleotide analogue prodrug that perturbs viral replication. Remdesivir has been used in various trials previously for the treatment of Coronavirus Disease 2019 (COVID-19). Some clinical trials found that remdesivir had a mortality benefit, while other studies did not. It was also seen that remdesivir shortened the duration of hospital stay among COVID-19 patients in some trials while in other trials remdesivir did not have any influence on the duration of hospital stay.

Aim: To study the clinical outcomes of remdesivir in moderate and severe cases of COVID-19.

Materials and Methods: The present retrospective, cohort study was conducted in the Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India, from September 2021 to May 2022, in which 400 case records of patients admitted with moderate to severe COVID-19 were studied. Among these 314 patients received remdesivir and 86 patients did not receive remdesivir. Categorical variables, nominal variables were represented as proportions and frequencies and continuous variables were represented as mean±SD. Statistical analysis was done using Chi-square test.

Results: A total of 400 COVID-19 patients were included in the study, among which 314 received remdesivir and 86 did not receive remedisivir. Those who received remdesivir had a mortality rate of 13.69% as compared to 11.63% among those who did not receive remdesivir (p-value=0.6170). In the remdesivir group, 36.62% had a hospital stay of >11 days, while it was 30.23% among the non remedisivir group (p-value=0.3060).

Conclusion: According to this study, remdesivir did not reduce mortality nor did it reduce the duration of hospital stay among moderate to severe COVID-19 patients.


Coronavirus disease 2019, Mechanical support, Oxygen support

Remdesivir is a nucleotide analogue prodrug that perturbs viral replication (1). It is found to be effective against many Ribonucleic Acid (RNA) viruses like Ebolavirus (EBOV) and the respiratory pathogens, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory syndrome (SARS-CoV), and SARS-CoV-2 (2). When the drug was first introduced by Gilead sciences, it was tested to check its effectiveness against Ebola virus in a trial and it was found to be inferior to the antibodies used in the trial (3). The Food and Drug Administration (FDA) approved this drug on 22nd October 2020 as the first antiviral drug in the treatment of Coronavirus Disease 2019 (COVID-19) subsequent to an emergency use authorisation dated May 1, 2020; the approval of remdesivir was supported by the agency data analysis from three randomised controlled clinical trials that included adult patients and children >12 years hospitalised with mild-to-severe COVID-19 (4). The Adaptive COVID-19 Treatment Trial 1 (ACTT1), a multicentre trial was conducted in various nations in which it was found that, the individuals who tested positive for COVID-19 and also who were on remdesivir treatment with oxygen support or on ventilator support fared well in comparison with those who did not receive remdesivir (5).

The ACCT1 study that was done among those with COVID-19 and who had lower respiratory tract infection it was found that, remdesivir was better than placebo as those who received remdesivir had a shorter time to recovery and lesser mortality when compared to those who received placebo. Those who received remdesivir had a median recovery time of 10 days as compared with 15 days among those who received placebo. The mortality rates were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (5). The second clinical trial was a randomised open labelled trial that was done among those with moderate COVID-19 disease in which it was found that, those randomised to a 10 day course of remdesivir did not have a better clinical status than those assigned to standard care at 11 days of treatment (6). In the third clinical trial in which patients were assigned either to receive 5 days or 10 days of remdesivir it was found that there was no difference in the clinical status of individuals between the two groups at the end of 14 days (7). In another study done among those with severe COVID-19 with clinical symptoms for lesser than 10 days it was found that, those who received remdesivir took a shorter time to clinically improve when compared to those who received placebo, but it was not statistically significant (8).

In a study done among COVID- 19 patients in which remdesivir was used on a compassionate-basis, 53 patients were treated with remdesivir and it was found that a significant number of them showed an improvement in oxygen support class and a good number of them who were on mechanical ventilation were extubated. Also mortality rate was low both among them who were not mechanically ventilated as well as those who were mechanically ventilated (9). However, in the solidarity that is an international clinical trial that evaluated the effect of four drugs: remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon on COVID-19 outcomes, it was found that all 4 treatments did not influence mortality, initiation of ventilation or duration of hospital stay among those who were hospitalised (10). In another study it was found that remdesivir had little or no difference to all cause mortality at upto 28 days (11).

Even though there are conflicting reports regarding the efficacy of remdesivir in treatment of COVID-19 from various trials, remdesivir was prescribed extensively in the country from 2020 to 2021. Hence, the present retrospective study was aimed to study the clinical outcomes of remdesivir in the management of COVID-19.

Material and Methods

This retrospective cohort study was conducted in the Department of General Medicine, SDM Medical College and Hospital, Dharwad, Karnataka, India, from September 2021 to May 2022. COVID-19 cases admitted to the hospital during the years July 2020 to June 2021 were considered for the study. After obtaining Institutional Ethics Committee approval (SDMIEC/2021/113) the data collection was initiated.

Inclusion criteria: All diagnosed cases of moderate or severe COVID-19 based on Reverse Transcription Polymerase Chain Reaction (RT-PCR), aged ≥18 years were included in the study. The severity classification was based on the Government of India (12) and National Institutes of Health (NIH), guidelines (13).

Exclusion criteria: Pregnancy, presence of chronic kidney disease, chronic liver disease AST ≥5 times upper limit of normal, creatinine clearance ≤30 mL/min respectively), <18 years of age and duration of hospital stay <48 hours were excluded from the study.

Study Procedure

The records of patients admitted from July 2020 to June 2021 were identified by International Classification of Diseases-10 (ICD-10) code U07.1. Remdesivir was given as advised by the physician as 200 mg stat followed by 100 mg once a day for five days. The data was collected of age, gender, duration of hospital stay, death, co-morbidities, moderate and severe COVID, Acute Kidney Injury (AKI), exposed to remdesivir or not, administration of other drugs like glucocorticoids, anticoagulants, and whether mechanical ventilation, inotropic support and oxygen were given.

Statistical Analysis

Categorical variables, nominal variables were represented as proportions and frequencies. Continuous variables were represented as mean±SD. Chi-square test was done for significance and p-value <0.05 was considered statistically significant.


The severity of COVID-19, mean age and gender distribution were similar in both the groups. The age of >60 years was taken as a cut-off, above which people were considered to be elderly and this parameter was also analysed to depict how many were old aged among those who received remdesivir and those who did not. Among the co-morbidities, a majority of population in both groups had hypertension and diabetes mellitus. (Table/Fig 1). The patients who received oxygen, anticoagulants and glucocorticoids were significantly more in the remdesivir group (Table/Fig 2).

There were more number of deaths recorded in the remdesivir group than the non remdesivir group, but it was not statistically significant (p-value=0.6170) (Table/Fig 3). A cut-off of 11 days was considered for comparison of duration of hospitalisation because 11 days was the average duration of hospital stay. Although not significant, there was a longer duration of hospital stay among those who received remdesivir (Table/Fig 3).


The study found that there was no difference in the mortality rate among those who received remdesivir in comparison to those who did not. In a retrospective cohort study it was found that those who received remdesivir did not show any significant mortality benefit when compared to those who did not (14). However, in a systematic review and meta-analysis it was found that remdesivir significantly reduced the mortality when compared to placebo (15). The authors felt that remdesivir usage might have yielded a mortality benefit as remdesivir was only used in the less severe COVID-19 wave and not in the more severe wave.

In this study, it was found that there was a marginally longer duration of hospital stay in those who received remdesivir than those who did not. This might be because those who received remdesivir were also those who had a more severe disease. Ohl ME et al., found that the duration of hospital stay was longer in those who received remdesivir than those who did not. This was because those who received remdesivir required to receive it for a minimum of five days while those who did not were discharged on days 3 or 4 (14). This is in contrast to the ACCT1 trial that demonstrated 10 days time to recovery among those who received remdesivir as against 15 days among those who received placebo (5).


A clinical trial could not be conducted, to assess the impact of remdesivir in the management of moderate to severe COVID-19 cases. The guidelines of classification of the severity of the disease and its management kept changing with time, this may have influenced the treatment and hence the results.


According to this study, although mortality was marginally higher among those who received remdesivir it was not significant. Also, more number of patients in the remdesivir group had a long duration of hospital stay compared to those who did not receive remedesivir, which was not statistically significant. Hence, more clinical trials are required to study the clinical outcomes of remedesivir in COVID-19 patients.


Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672-83. [crossref] [PubMed]
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34(1):e00162-20. [crossref] [PubMed]
Mulangu S, Dodd LE, Jr Davey RT, Mbaya OT, Proschan M, Mukadi D et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-03. Doi: 10.1056/NEJMoa1910993. [crossref] [PubMed]
FDA. FDA approves first treatment for COVID-19. 2020. Available from: https://www.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 study group members. Remdesivir for the treatment of Covid-19- Final report. N Engl J Med. 2020;383(19):1813-26. [crossref] [PubMed]
Spinner CD, Gottlieb RL, Criner GJ, Lopez JRA, Cattelan AM, Viladomiu AS, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical Trial. JAMA. 2020;324(11):1048-57. [crossref] [PubMed]
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827-37. [crossref] [PubMed]
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78. [crossref] [PubMed]
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-36. [crossref] [PubMed]
WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19- Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497-11. [crossref] [PubMed]
Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):CD014962. [crossref] [PubMed]
Clinical Management Protocol: COVID-19 Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division).https:// 2.15/10/2022.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.
Ohl ME, Miller DR, Lund BC, Kobayashi T, Richardson Miell K, Beck BF, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Netw Open. 2021;4(7):e2114741. [crossref] [PubMed]
Bansal V, Mahapure KS, Bhurwal A, Gupta I, Hassanain S, Makadia J, et al. Mortality benefit of remdesivir in COVID-19: A systematic review and meta-analysis. Front Med (Lausanne). 2021;7:606429. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2023/61270.17403

Date of Submission: Nov 05, 2022
Date of Peer Review: Dec 02, 2022
Date of Acceptance: Dec 26, 2022
Date of Publishing: Jan 01, 2023

• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? NA
• For any images presented appropriate consent has been obtained from the subjects. NA

• Plagiarism X-checker: Nov 21, 2022
• Manual Googling: Dec 09, 2022
• iThenticate Software: Dec 24, 2022 (20%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)